Israel News App

Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population – Novartis

Written by

admin

in

  1. Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population  Novartis
  2. Timothée Olivier: Revisiting NATALEE Results Through Sensitivity Analyses  Oncodaily
  3. Novartis…

Continue Reading